Have a personal or library account? Click to login
Looking through the imaging perspective: the importance of imaging necrosis in glioma diagnosis and prognostic prediction – single centre experience Cover

Looking through the imaging perspective: the importance of imaging necrosis in glioma diagnosis and prognostic prediction – single centre experience

Open Access
|Feb 2024

Figures & Tables

FIGURE 1.

Representative ROI delineations. A 53-year-old man was diagnosed with glioblastoma, IDH-wildtype. (A) contrastenhanced T1-weighted image (T1WI-CE); (B) the time-signal intensity curve; (C) the transfer constant (ktrans) image; (D) rate constant (kep) image; (E) extravascular extracellular volume fraction (ve) image; (F) initial area under the curve in the first 60 s (iauc) image. On images, B-F, ROI 1 marked green represented tumor parenchyma, ROI 2 marked yellow represented the peripheral zones, and ROI 3 marked blue-turquoise represented contralateral normal-appearing brain tissues.
Representative ROI delineations. A 53-year-old man was diagnosed with glioblastoma, IDH-wildtype. (A) contrastenhanced T1-weighted image (T1WI-CE); (B) the time-signal intensity curve; (C) the transfer constant (ktrans) image; (D) rate constant (kep) image; (E) extravascular extracellular volume fraction (ve) image; (F) initial area under the curve in the first 60 s (iauc) image. On images, B-F, ROI 1 marked green represented tumor parenchyma, ROI 2 marked yellow represented the peripheral zones, and ROI 3 marked blue-turquoise represented contralateral normal-appearing brain tissues.

FIGURE 2.

Representative MR images with imaging necrosis derived from a 53-year-old man with glioblastoma, IDH-wildtype. Shown from left to right by the order are T1WI (A), T2WI (B), and T1WI-CE (C).
Representative MR images with imaging necrosis derived from a 53-year-old man with glioblastoma, IDH-wildtype. Shown from left to right by the order are T1WI (A), T2WI (B), and T1WI-CE (C).

FIGURE 3.

Some representative MRI images without imaging necrosis which was exactly confused in diagnosing imaging necrosis. Shown from left to right by the order are T1WI, T2WI, and T1WI-CE. (A) a 24-year-old man with an oligodendroglioma, IDH-mutant and 1p/19q-deleted, CNS WHO grade 2; (B) a 39-year-old man with an oligodendroglioma, IDH-mutant and 1p/19q-deleted, CNS WHO grade 2; (C) a 55-year-old woman with an oligodendroglioma, IDHmutant and 1p/19q-deleted, CNS WHO grade 2; (D) a 45-year-old man with an astrocytoma, CNS IDH-mutant, WHO grade 2; (E) a 36-year-old woman with an oligodendroglioma, IDH-mutant and 1p/19q-deleted, CNS WHO grade 2. In this case (E), it showed multiple long tubular and filiform enhancement and there were some tumor areas with remarked decrease of reinforcement. But these areas are hyperintense, not hypointense, on the T1-weighted image. Comparing with CT images (not provided), calcification on these areas were just observed. So, there was no imaging necrosis in these conditions.
Some representative MRI images without imaging necrosis which was exactly confused in diagnosing imaging necrosis. Shown from left to right by the order are T1WI, T2WI, and T1WI-CE. (A) a 24-year-old man with an oligodendroglioma, IDH-mutant and 1p/19q-deleted, CNS WHO grade 2; (B) a 39-year-old man with an oligodendroglioma, IDH-mutant and 1p/19q-deleted, CNS WHO grade 2; (C) a 55-year-old woman with an oligodendroglioma, IDHmutant and 1p/19q-deleted, CNS WHO grade 2; (D) a 45-year-old man with an astrocytoma, CNS IDH-mutant, WHO grade 2; (E) a 36-year-old woman with an oligodendroglioma, IDH-mutant and 1p/19q-deleted, CNS WHO grade 2. In this case (E), it showed multiple long tubular and filiform enhancement and there were some tumor areas with remarked decrease of reinforcement. But these areas are hyperintense, not hypointense, on the T1-weighted image. Comparing with CT images (not provided), calcification on these areas were just observed. So, there was no imaging necrosis in these conditions.

FIGURE 4.

Survival curves for cases of imaging necrosis (A), cases of pathological necrosis (B), and cases of both pathological and imaging necrosis (C).
Survival curves for cases of imaging necrosis (A), cases of pathological necrosis (B), and cases of both pathological and imaging necrosis (C).

Participant demographic findings

ParametersTypeImaging necrosis
Sumt/χ2bp
Negative n (%)Positive n (%)
Age (n = 150)-40.54±11.08 (n = 54)50.39±12.47 (n = 96)-−4.829&p < 0.001
Sex (n = 150)male36(66.67)68(70.83)1040.2820.595
female18(33.33)28(29.17)46
IDH (n = 144)wildtype17(32.08)69(75.82)8626.649p < 0.001
mutant36(67.92)22(24.18)58
1p19q (n = 109)non-codeletion23(51.11)55(85.94)7815.746p < 0.001
codeletion22(48.89)9(14.06)31
CDKN2A/B homozygous deletion (n = 63)non-deletion38(100.00)20(80.00)585.745b0.017*
deletion0(0.00)5(20.00)5
EGFR amplification (n = 81)non-amplification8(66.67)45(65.22)530.054a0.817
amplification4(33.33)24(34.78)28
chr7 gain/10 loss (n = 26)negative10(83.33)13(92.86)230.552b0.457
positive2(16.67)1(7.14)3
Grade (n = 119)high-grade6(16.22)70(85.37)7652.828p < 0.001
low-grade31(83.78)12(14.63)43
WHO grade (n = 119)WHO grade 226(70.27)4(4.88)3062.664ap < 0.001
WHO grade 35(13.51)8(9.76)13
WHO grade 46(16.22)70(85.37)76
Integrated histo-molecular diagnoses (n = 116)Oligodendroglioma, IDH-mutant and 1p/19q-deleted17(45.95)7(8.86)2441.238p < 0.001
Astrocytoma, IDH-mutant15(40.54)12(15.19)27
Glioblastoma, IDH-wildtype5(13.51)60(75.95)65

Representative results of non-parametric tests and ROC analyses between DCE-related data for gliomas with or without pathological necrosis/imaging necrosis

ParameterpAUC (95% CI)SensitivitySpecificityCut-off
Panecrosis
Tumor-ktrans-Mean< 0.0010.824 (0.711 ~0.936)0.940.6250.07
Edema-ktrans-Mean0.031*0.655 (0.527 ~ 0.783)0.8330.460.03
Tumor-ve-Mean< 0.0010.891 (0.788 ~ 0.995)0.960.8330.17
Edema-ve-Mean0.002**0.728 (0.613 ~ 0.842)0.3410.16
Tumor-kep-Mean< 0.0010.872 (0.761 ~ 0.983)0.8330.862.48
Tumor-iauc-Mean< 0.0010.899 (0.803 ~ 0.996)10.750.07
Imnecrosis
Tumor-ktrans-Mean< 0.0010.856 (0.772 ~ 0.939)0.8770.7570.08
Tumor-ve-Mean< 0.0010.929 (0.872 ~ 0.986)0.8920.9190.17
Edema-ve-Mean0.005**0.667 (0.558 ~ 0.776)0.7080.5950.06
Tumor-kep-Mean< 0.0010.914 (0.857 ~ 0.971)0.9460.8312.74
Tumor-iauc-Mean< 0.0010.909 (0.844 ~ 0.974)0.80.9460.13

Detailed clinical, imaging and pathological information of Only Imnecrosis group and Only Panecrosis group

GroupGradeSexAgeOS (month)IDH (0:wild; 1:mutant)1p19q (0:non-codeletion; 1:codeletion)CDKN2A/B (0:non-deletion; 1:deletion)EGFR amplification (0:non-amplification; 1:amplification)chr7 gain/10 loss (0:negative; 1:positive)Pathology
Only Panecrosis groupWHO CNS grade 4female632.5100NANAAstrocytoma, IDH-mutant
Only Panecrosis groupCNS WHO grade 4female552000NA0NAGlioblastoma, IDH-wildtype
Only Panecrosis groupCNS WHO grade 2female36NA110NANAOligodendroglioma, IDH-mutant and 1p/19q-deleted
Only Panecrosis groupNAfemale34NA1NANANANAIDH-mutation, NOS
Only Imnecrosis groupCNS WHO grade 4male64500NA1NAGlioblastoma, IDH-wildtype
Only Imnecrosis groupCNS WHO grade 2male4025100NANAAstrocytoma, IDH-mutant
Only Imnecrosis groupCNS WHO grade 3female5560.06110NANAOligodendroglioma, IDH-mutant and 1p/19q-deleted
Only Imnecrosis groupCNS WHO grade 2male265.3910000Astrocytoma, IDH-mutant
Only Imnecrosis groupNQmale407.1900NA0NAIDH-wildtype, NOS
Only Imnecrosis groupNAmale2819.6800NA00IDH-wildtype, NOS
Only Imnecrosis groupCNS WHO grade 3male2634.42100NANAAstrocytoma, IDH-mutant
DOI: https://doi.org/10.2478/raon-2024-0014 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 23 - 32
Submitted on: Sep 19, 2023
Accepted on: Dec 1, 2023
Published on: Feb 21, 2024
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year

© 2024 Hui Ma, Shanmei Zeng, Dingxiang Xie, Wenting Zeng, Yingqian Huang, Liwei Mazu, Nengjin Zhu, Zhiyun Yang, Jianping Chu, Jing Zhao, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.